The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on the heels of a positive Phase III study in adolescent patients, appears set to gain expanded approval in this population beginning in 2019, and the late-stage pipeline features compelling programs, including Pfizer’s abrocitinib and AbbVie’s upadacitinib. Pediatric patients comprise a sizable percentage of the AD population, and clinicians appear to manage them with a risk tolerance that is lower than accepted in adult patients. We will assess the commercial opportunity in the pediatric, topical-refractory, moderate to severe AD space through a comprehensive look at the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the appeal of potential AD products in the pediatric population.
QUESTIONS ANSWERED
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European dermatologists treating pediatric patients
Key companies: Sanofi, Regeneron, Pfizer, AbbVie, LEO Pharma, Eli Lilly, Incyte, Vanda, Novartis, Galderma, Dermira
Key drugs: Dupixent, cyclosporine, methotrexate, azathioprine, mycophenolate, oral prednisone
KEY METRICS INCLUDED
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.